The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes

2015 ◽  
Vol 12 (2) ◽  
Author(s):  
Farzad Shidfar ◽  
Asadollah Rajab ◽  
Tayebeh Rahideh ◽  
Nafiseh Khandouzi ◽  
Sharieh Hosseini ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Zingiber Officinale ◽  
Serum Glucose ◽  
Double Blind ◽  
Old Patients ◽  
Reactive Protein ◽  
Total Antioxidant ◽  
Glycemic Indices ◽  
Serum Paraoxonase

Abstract: Ginger (: A double-blind, placebo-controlled, randomized clinical trial was conducted on 20–60 -year-old patients with type 2 diabetes who did not receive insulin. Participants in the intervention and control groups were received 3 g of powdered ginger or placebo (lactose) (in capsules) daily for 3 months. Glycemic indices, total antioxidant capacity (TAC), malondialdehyde (MDA), C-reactive protein (CRP), serum paraoxonase, dietary intake and physical activity were measured at the beginning and end of the study, and after 12 h fasting.: Comparison of the indices after 3 months showed that the differences between the ginger and placebo groups were statistically significant as follows: serum glucose (–19.41±18.83 vs. 1.63±4.28 mg/dL, p<0.001), HbA: This report shows that the 3 months supplementation of ginger improved glycemic indices, TAC and PON-1 activity in patients with type 2 diabetes.

scholarly journals Effectiveness of ginger in reducing metabolic levels in people with diabetes: a randomized clinical trial

2020 ◽  
Vol 28 ◽  
Author(s):  
Gerdane Celene Nunes Carvalho ◽  
José Claudio Garcia Lira-Neto ◽  
Márcio Flávio Moura de Araújo ◽  
Roberto Wagner Júnior Freire de Freitas ◽  
Maria Lúcia Zanetti ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Blood Sugar ◽  
Zingiber Officinale ◽  
Secondary Outcome ◽  
Control Group ◽  
Double Blind ◽  
Experimental Group ◽  
Hba1c Levels

Objective: to evaluate the effectiveness of ginge (Zingiber officinale) in reducing blood sugar and lipid levels in people with type 2 diabetes. Method: a randomized and double-blind clinical trial conducted with people with type 2 diabetes in primary care facilities. The study included individuals aged between 20 and 80 years old, using oral antidiabetic drugs and with HbA1c levels between 6.0% and 10%. The participants were paired 1:1, allocated in two distinct groups, and randomized in blocks, based on their HbA1c levels. In the experimental group, the participants used 1.2g of ginger and, in the control group, 1.2g of placebo, daily for 90 days. The primary outcome was a reduction in fasting blood sugar and HbA1c, and the secondary outcome was a reduction in lipids and HOMA-IR. 103 individuals completed the study, 47 in the experimental group and 56 in the control group. Results: the participants in the experimental group showed a greater reduction in the blood glucose and total cholesterol values compared to the control group. Conclusion: the use of ginger can help in the treatment of people with diabetes, and data support the inclusion of this herbal drug in the clinical practice of nurses. RBR-2rt2wy

scholarly journals The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome

2020 ◽  
Vol 9 (7) ◽  
pp. 715-723
Author(s):  
Milica Popovic ◽  
Fahim Ebrahimi ◽  
Sandrine Andrea Urwyler ◽  
Marc Yves Donath ◽  
Mirjam Christ-Crain
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Surrogate Marker ◽  
Low Grade ◽  
Double Blind Study ◽  
Double Blind ◽  
Protein Levels ◽  
Reactive Protein ◽  
Low Grade Inflammation

Arginine vasopressin (AVP) was suggested to contribute to cardiovascular risk and type 2 diabetes in patients with metabolic syndrome. The proinflammatory cytokine interleukin (IL)-1 is able to induce AVP secretion and plays a causal role in cardiovascular mortality and type 2 diabetes. We investigated in two studies whether copeptin levels – the surrogate marker for AVP – are regulated by IL-1-mediated chronic inflammation in patients with metabolic syndrome. Study A was a prospective, interventional, single-arm study (2014–2016). Study B was a randomized, placebo-controlled, double-blind study (2016–2017). n = 73 (Study A) and n = 66 (Study B) adult patients with metabolic syndrome were treated with 100 mg anakinra or placebo (only in study B) twice daily for 1 day (study A) and 28 days (study B). Fasting blood samples were drawn at day 1, 7, and 28 of treatment for measurement of serum copeptin. Patients with chronic low-grade inflammation (C-reactive protein levels ≥2 mg/L) and BMI >35 kg/m2 had higher baseline copeptin levels (7.7 (IQR 4.9–11.9) vs 5.8 (IQR 3.9–9.3) pmol/L, Pinflamm = 0.009; 7.8 (IQR 5.4–11.7) vs 4.9 (IQR 3.7–9.8) pmol/L, PBMI = 0.008). Copeptin levels did not change either in the anakinra or in the placebo group and remained stable throughout the treatment (P = 0.44). Subgroup analyses did not reveal effect modifications. Therefore, we conclude that, although IL-1-mediated inflammation is associated with increased circulating copeptin levels, antagonizing IL-1 does not significantly alter copeptin levels in patients with metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document